Quilseconazole free base · Synonyms: VT-1129

Quilseconazole is a potent, orally active fungal Cyp51 inhibitor.

For research use only. Not for human or veterinary use.

Target Fungal Cytochrome P450

Research area Infection Inflammation/Immunology

Purity >98% Stock Inquire

Data Sheet SDS COA

Quilseconazole structure

CAS No.: 1340593-70-5

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 520.00	BP-01871-25mg	In stock	Get quote
50 mg	USD 820.00	BP-01871-50mg	In stock	Get quote
100 mg	USD 1,220.00	BP-01871-100mg	In stock	Get quote
250 mg	USD 2,120.00	BP-01871-250mg	In stock	Get quote
500 mg	Inquire	BP-01871-500mg	In stock	Inquire
1 g	Inquire	BP-01871-1g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

Quilseconazole (VT-1129) is a potent, orally active fungal Cyp51 (lanosterol 14-α-demethylase) inhibitor, binds tightly to cryptococcal CYP51, but weakly inhibits humans CYP450 enzymes.

Biological activity

Quilseconazole exhibits potent antifungal activity against Cryptococcus neoformans and Cryptococcus gattii VT-1129 (0.15-30 mg/kg; oral gavage; 10-14 days) shows antifungal activity in a mouse model of cryptococcal meningitis Pharmacokinetic Analysis inMale CD-1 Mice

Identifiers

SMILES: O[C@@](CN1C=NN=N1)(C(C=CC(F)=C2)=C2F)C(F)(C3=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=N3)F
InChIKey: NCEHACHJIXJSPD-FQEVSTJZSA-N

Specifications

MW (average): 513.3677
Formula: C₂₂H₁₄F₇N₅O₂
CAS No.: 1340593-70-5
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO : 100 mg/mL

Documents

References

[1]. Lockhart SR, et al. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31.

[2]. Wiederhold NP, et al. In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01315-18.

[3]. Warrilow AG, et al. The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4530-8.

Same target

Search Fungal

Same research area

Search Infection